Bastide Le Confort Médical SA (EPA:BLC) Just Reported, And Analysts Assigned A €28.17 Price Target

Bastide Le Confort Médical SA (EPA:BLC) shareholders are probably feeling a little disappointed, since its shares fell 6.7% to €18.70 in the week after its latest annual results. It was an okay result overall, with revenues coming in at €530m, roughly what the analysts had been expecting. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

View our latest analysis for Bastide Le Confort Médical

Taking into account the latest results, the consensus forecast from Bastide Le Confort Médical's three analysts is for revenues of €561.5m in 2025. This reflects a credible 6.0% improvement in revenue compared to the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of €559.6m and earnings per share (EPS) of €3.04 in 2025. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results.

Intriguingly,the analysts have cut their price target 6.6% to €28.17 showing a clear decline in sentiment around Bastide Le Confort Médical's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Bastide Le Confort Médical, with the most bullish analyst valuing it at €30.00 and the most bearish at €25.50 per share. This is a very narrow spread of estimates, implying either that Bastide Le Confort Médical is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's pretty clear that there is an expectation that Bastide Le Confort Médical's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 6.0% growth on an annualised basis. This is compared to a historical growth rate of 9.1% over the past five years. Compare this to the 5 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 5.0% per year. So it's pretty clear that, while Bastide Le Confort Médical's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.

The Bottom Line

The clear take away from these updates is that the analysts made no change to their revenue estimates for next year, with the business apparently performing in line with their models. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Bastide Le Confort Médical's future valuation.

We have estimates for Bastide Le Confort Médical from its three analysts out to 2027, and you can see them free on our platform here.

You should always think about risks though. Case in point, we've spotted 3 warning signs for Bastide Le Confort Médical you should be aware of, and 1 of them is significant.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.